Summit Therapeutics (SMMT) said Friday its partner Akeso has received approval from China's National Medical Products Administration for a second use of ivonescimab.
The approval was based on results from a phase 3 clinical trial, called HARMONi-2, which tested ivonescimab alone against pembrolizumab alone in patients with advanced non-small cell lung cancer that shows PD-L1 protein, the company said.
Following NMPA's instructions, Akeso conducted an interim analysis of overall survival and reported a hazard ratio of 0.777, based on 39% of the total data collected so far, it added.
Summit is also running the HARMONi-7 trial, a global phase 3 study evaluating ivonescimab against pembrolizumab in a similar group of NSCLC patients for regulatory approval in the United States and other licensed regions, according to the company.
Shares of the company were down nearly 32% in recent trading.
Price: 23.42, Change: -13.29, Percent Change: -36.20
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。